American Biosecurity Initiative Responds to Proposed Outbound Investment Rules
American Biosecurity Initiative Responds to Proposed Outbound Investment Rules
PR Newswire
WASHINGTON, Oct. 23, 2026
WASHINGTON, Oct. 23, 2026 /PRNewswire/ -- Yesterday, the U.S. Department of the Treasury proposed regulations implementing the Comprehensive Outbound Investment National Security (COINS) Act. The proposal would expand U.S. outbound investment restrictions to cover a broad range of biotechnology activities, including the development of pharmaceutical compounds, biological sequencing, bioinformatics, and biomanufacturing technologies. The proposed rules would prohibit certain U.S. investments in covered foreign entities engaged in these activities, including equity investments, certain financing arrangements, and joint ventures.
The American Biosecurity Initiative's executive director, Jennifer Crook, issued the following statement:
"America's leadership in biotechnology is essential to our national security, economic competitiveness, and ability to develop new medicines. Protecting sensitive technologies from foreign adversaries is important, and so is preserving America's ability to develop those technologies at home and ensure patients can access promising new treatments.
"Treasury's proposed restrictions on outbound biotechnology investment must address specific national security risks without unnecessarily discouraging investment, slowing innovation, or placing American companies at a competitive disadvantage. Maintaining America's biotechnology leadership must remain a central part of our national security strategy."
About ABI
The American Biosecurity Initiative brings together experts in biotechnology, defense, and intelligence to advance policies that strengthen U.S. national security and biotechnology leadership. To learn more, visit americanbiosecurity.org.
MEDIA CONTACT:
Sarah Mojica Arango
(202) 990-1407
425511@email4pr.com
SOURCE American Biosecurity Initiative
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States